Drug Profile

Sibeprenlimab - Visterra

Alternative Names: Sibeprenlimab-szsi; VIS-649; VOYXACT

Latest Information Update: 28 Oct 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Visterra
Class Antirheumatics; Monoclonal antibodies; Urologics
Mechanism of Action Tumour necrosis factor ligand superfamily member 13 inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - IgA nephropathy
New Molecular Entity Yes

Highest Development Phases

Marketed IgA nephropathy
Phase II Focal segmental glomerulosclerosis; Lipoid nephrosis; Membranous glomerulonephritis; Sjogren's syndrome

Most Recent Events

23 Oct 2026 Phase-II clinical trials in Focal segmental glomerulosclerosis (SC) (NCT07861113)
23 Oct 2026 Phase-II clinical trials in Lipoid-nephrosis (SC) (NCT07861113)
23 Oct 2026 Phase-II clinical trials in Membranous glomerulonephritis (SC) (NCT07861113)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com